Équipe 3 – Publications

MAP2/TGN-46/DAPI

Culture primaire de neurones corticaux (marquages fluorescents ciblant les protéines  MAP2, TGN-46 et le noyau DAPI).

PPP2CA LRRK2

Culture primaire de neurones corticaux (marquages fluorescents ciblant les protéines  PPP2CA et LRRK2).

CRISPR/Cas9

Représentation schématique du système CRISPR/Cas9 permettant de réprimer ou d’activer de façon efficace la transcription dans les cellules humaines.
(A) Le domaine dCas9 se lie à une séquence spécifique de l’ADN via une séquence guide ARN de 20 nucléotides suivie d’une séquence PAM (NGG). Selon l’effecteur fusionné, la transcription sera activée (CRISPRa) ou réprimée (CRISPRi).
(B) Des cellules SH-SY5Y exprimant de manière stable dCas9-KRAB ou dCas9-VP64 ont été infectées avec des constructions de lentivirus exprimant un ARNg contrôle ou deux ARNg différents ciblant PPP1R1B.

Équipe Étapes précoces dans la maladie de Parkinson
Vous êtes ici : Accueil > Stades précoces de la maladie de Parkinson > PUBLICATIONS

ÉQUIPE STADES PRÉCOCES DE LA MALADIE DE PARKINSON

PUBLICATIONS

2018 | 2017 | 2016 | 2015 | 2014 | 2013

 

PUBLICATIONS 2018

1. Madero-Pérez J, Fdez E, Fernández B, Lara Ordóñez AJ, Blanca Ramírez M, Gómez-Suaga P, Waschbüsch D, Lobbestael E, Baekelandt V, Nairn AC, Ruiz-Martínez J, Aiastui A, López de Munain A, Lis P, Comptdaer T, Taymans JM, Chartier-Harlin MC, Beilina A, Gonnelli A, Cookson MR, Greggio E, Hilfiker S. Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation. Mol Neurodegener. 2018 Jan 23;13(1):3. doi: 10.1186/s13024-018-0235-y.

 

PUBLICATIONS 2017

2. Civiero L, Cogo S, Kiekens A, Morganti C, Tessari I, Lobbestael E, Baekelandt V, Taymans JM, Chartier-Harlin MC, Franchin C, Arrigoni G, Lewis PA, Piccoli G, Bubacco L, Cookson MR, Pinton P, Greggio E. PAK6 Phosphorylates 14-3-3γ to Regulate Steady State Phosphorylation of LRRK2. Front Mol Neurosci. 2017 Dec 14;10:417. doi: 10.3389/fnmol.2017.00417.

3. Belarbi K, Cuvelier E, Destée A, Gressier B, Chartier-Harlin MC. NADPH oxidases in Parkinson’s disease: a systematic review. Mol Neurodegener. 2017 Nov 13;12(1):84. doi: 10.1186/s13024-017-0225-5. Review.

4. Aerts C, Cassim F, Strubi-Vuillaume I, Destée A, Sablonnière B, Collod-Béroud G, Defebvre L, Kreisler A. Writing tremor: Should we look for a TOR1A mutation? J Neurol Sci. 2017 Nov 15;382:146-147. doi: 10.1016/j.jns.2017.09.048.

5. Sejwal K, Chami M, Rémigy H, Vancraenenbroeck R, Sibran W, Sütterlin R, Baumgartner P, McLeod R, Chartier-Harlin MC, Baekelandt V, Stahlberg H, Taymans JM. Cryo-EM analysis of homodimeric full-length LRRK2 and LRRK1 protein complexes. Sci Rep. 2017 Aug 17;7(1):8667. doi: 10.1038/s41598-017-09126-z.

6. Rassu M, Del Giudice MG, Sanna S, Taymans JM, Morari M, Brugnoli A, Frassineti M, Masala A, Esposito S, Galioto M, Valle C, Carri MT, Biosa A, Greggio E, Crosio C, Iaccarino C. Role of LRRK2 in the regulation of dopamine receptor trafficking. PLoS One. 2017 Jun 5;12(6):e0179082. doi: 10.1371/journal.pone.0179082.

7. Blanca Ramírez M, Lara Ordóñez AJ, Fdez E, Madero-Pérez J, Gonnelli A, Drouyer M, Chartier-Harlin MC, Taymans JM, Bubacco L, Greggio E, Hilfiker S. GTP binding regulates cellular localization of Parkinson’s disease-associated LRRK2. Hum Mol Genet. 2017 Jul 15;26(14):2747-2767. doi: 10.1093/hmg/ddx161.

8. Verny C, Bachoud-Lévi AC, Durr A, Goizet C, Azulay JP, Simonin C, Tranchant C, Calvas F, Krystkowiak P, Charles P, Youssov K, Scherer C, Prundean A, Olivier A, Reynier P, Saudou F, Maison P, Allain P, von Studnitz E, Bonneau D; CYST-HD Study Group. A randomized, double-blind, placebo-controlled trial evaluating cysteamine in Huntington’s disease. Mov Disord. 2017 Jun;32(6):932-936. doi: 10.1002/mds.27010.

9. Nkiliza A, Chartier-Harlin MC. ATXN2 a culprit with multiple facets. Oncotarget. 2017 May 23;8(21):34028-34029. doi: 10.18632/oncotarget.17112.

10. Taymans JM. Regulation of LRRK2 by Phosphatases. Adv Neurobiol. 2017;14:145-160. doi: 10.1007/978-3-319-49969-7_8.

11. Taymans JM, Mutez E, Drouyer M, Sibran W, Chartier-Harlin MC. LRRK2 detection in human biofluids: potential use as a Parkinson’s disease biomarker? Biochem Soc Trans. 2017 Feb 8;45(1):207-212. doi: 10.1042/BST20160334. Review.

12. Moors TE, Hoozemans JJ, Ingrassia A, Beccari T, Parnetti L, Chartier-Harlin MC, van de Berg WD. Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease. Mol Neurodegener. 2017 Jan 25;12(1):11. doi: 10.1186/s13024-017-0154-3. Review.

 

PUBLICATIONS 2016

13. Stievenard A, Méquinion M, Andrews ZB, Destée A, Chartier-Harlin MC, Viltart O, Vanbesien-Mailliot CC. Is there a role for ghrelin in central dopaminergic systems? Focus on nigrostriatal and mesocorticolimbic pathways. Neurosci Biobehav Rev. 2017 Feb;73:255-275. doi: 10.1016/j.neubiorev.2016.11.021. Review.

14. Kreisler A, Verpraet AC, Veit S, Pennel-Ployart O, Béhal H, Duhamel A, Destée A. Clinical Characteristics of Voice, Speech, and Swallowing Disorders in Oromandibular Dystonia. J Speech Lang Hear Res. 2016 Oct 1;59(5):940-949. doi: 10.1044/2016_JSLHR-S-15-0169.

15. Nkiliza A, Mutez E, Simonin C, Leprêtre F, Duflot A, Figeac M, Villenet C, Semaille P, Comptdaer T, Genet A, Sablonnière B, Devos D, Defebvre L, Destée A, Chartier-Harlin MC. RNA-binding disturbances as a continuum from spinocerebellar ataxia type 2 to Parkinson disease. Neurobiol Dis. 2016 Dec;96:312-322. doi: 10.1016/j.nbd.2016.09.014.

16. de Diego-Balaguer R, Schramm C, Rebeix I, Dupoux E, Durr A, Brice A, Charles P, Cleret de Langavant L, Youssov K, Verny C, Damotte V, Azulay JP, Goizet C, Simonin C, Tranchant C, Maison P, Rialland A, Schmitz D, Jacquemot C, Fontaine B, Bachoud-Lévi AC; French Speaking Huntington Group. COMT Val158Met Polymorphism Modulates Huntington’s Disease Progression. PLoS One. 2016 Sep 22;11(9):e0161106. doi: 10.1371/journal.pone.0161106.

17. Marelli C, Guissart C, Hubsch C, Renaud M, Villemin JP, Larrieu L, Charles P, Ayrignac X, Sacconi S, Collignon P, Cuntz-Shadfar D, Perrin L, Benarrosh A, Degardin A, Lagha-Boukbiza O, Mutez E, Carlander B, Morales RJ, Gonzalez V, Carra-Dalliere C, Azakri S, Mignard C, Ollagnon E, Pageot N, Chretien D, Geny C, Azulay JP, Tranchant C, Claustres M, Labauge P, Anheim M, Goizet C, Calvas P, Koenig M. Mini-Exome Coupled to Read-Depth Based Copy Number Variation Analysis in Patients with Inherited Ataxias. Hum Mutat. 2016 Dec;37(12):1340-1353. doi: 10.1002/humu.23063.

18. Miltgen M, Blanchard A, Mathieu H, Kreisler A, Jean-Pierre-Desvignes, Salgado D, Roubertie A, Barre L, Rai G, Blanck V, Frederic M, Douay X, Mazzolenni R, Charpentier P, Gonzalez V, Destée A, Béroud C, Collod-Béroud G. Novel heterozygous mutation in ANO3 responsible for craniocervical dystonia. Mov Disord. 2016 Aug;31(8):1251-2. doi: 10.1002/mds.26717.

19. Leclair-Visonneau L, Rouaud T, Debilly B, Durif F, Houeto JL, Kreisler A, Defebvre L, Lamy E, Volteau C, Nguyen JM, Dily SL, Damier P, Boutoleau-Bretonnière C, Lejeune P, Derkinderen P. Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy. Clin Neurol Neurosurg. 2016 Jul;146:35-9. doi: 10.1016/j.clineuro.2016.04.021.

20. Hainque E, Vidailhet M, Cozic N, Charbonnier-Beaupel F, Thobois S, Tranchant C, Brochard V, Glibert G, Drapier S, Mutez E, Doe De Maindreville A, Lebouvier T, Hubsch C, Degos B, Bonnet C, Grabli D, Legrand AP, Méneret A, Azulay JP, Bissery A, Zahr N, Clot F, Mallet A, Dupont S, Apartis E, Corvol JC, Roze E. A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia. Neurology. 2016 May 3;86(18):1729-35. doi: 0.1212/WNL.0000000000002631.

21. Lesage S, Drouet V, Majounie E, Deramecourt V, Jacoupy M, Nicolas A, Cormier-Dequaire F, Hassoun SM, Pujol C, Ciura S, Erpapazoglou Z, Usenko T, Maurage CA, Sahbatou M, Liebau S, Ding J, Bilgic B, Emre M, Erginel-Unaltuna N, Guven G, Tison F, Tranchant C, Vidailhet M, Corvol JC, Krack P, Leutenegger AL, Nalls MA, Hernandez DG, Heutink P, Gibbs JR, Hardy J, Wood NW, Gasser T, Durr A, Deleuze JF, Tazir M, Destée A, Lohmann E, Kabashi E, Singleton A, Corti O, Brice A; French Parkinson’s Disease Genetics Study (PDG); International Parkinson’s Disease Genomics Consortium (IPDGC). Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. Am J Hum Genet. 2016 Mar 3;98(3):500-513. doi: 10.1016/j.ajhg.2016.01.014.

22. Taymans JM, Greggio E. LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson’s Disease, Where Do We Stand? Curr Neuropharmacol. 2016;14(3):214-25. Review.

 

PUBLICATIONS 2015

23. de Broucker A, Semaille P, Cailliau K, Martoriati A, Comptdaer T, Bodart JF, Destée A, Chartier-Harlin MC. Xenopus laevis as a Model to Identify Translation Impairment. J Vis Exp. 2015 Sep 27;(103). doi: 10.3791/52724.

24. Ratti PL, Nègre-Pagès L, Pérez-Lloret S, Manni R, Damier P, Tison F, Destée A, Rascol O. Subjective sleep dysfunction and insomnia symptoms in Parkinson’s disease: Insights from a cross-sectional evaluation of the French CoPark cohort. Parkinsonism Relat Disord. 2015 Nov;21(11):1323-9. doi: 10.1016/j.parkreldis.2015.09.025.

25. Civiero L, Cirnaru MD, Beilina A, Rodella U, Russo I, Belluzzi E, Lobbestael E, Reyniers L, Hondhamuni G, Lewis PA, Van den Haute C, Baekelandt V, Bandopadhyay R, Bubacco L, Piccoli G, Cookson MR, Taymans JM, Greggio E. Leucine-rich repeat kinase 2 interacts with p21-activated kinase 6 to control neurite complexity in mammalian brain. J Neurochem. 2015 Dec;135(6):1242-56. doi: 10.1111/jnc.13369.

26. Taymans JM, Nkiliza A, Chartier-Harlin MC. Deregulation of protein translation control, a potential game-changing hypothesis for Parkinson’s disease pathogenesis. Trends Mol Med. 2015 Aug;21(8):466-72. doi: 10.1016/j.molmed.2015.05.004. Review.

27. Cleret de Langavant L, Sudraud S, Verny C, Krystkowiak P, Simonin C, Damier P, Demonet JF, Supiot F, Rialland A, Schmitz D, Maison P, Youssov K, Bachoud-Lévi AC. Longitudinal study of informed consent in innovative therapy research: experience and provisional recommendations from a multicenter trial of intracerebral grafting. PLoS One. 2015 May 26;10(5):e0128209. doi: 10.1371/journal.pone.0128209.

28. Kambia N, Farce A, Belarbi K, Gressier B, Luyckx M, Chavatte P, Dine T. Docking study: PPARs interaction with the selected alternative plasticizers to di(2-ethylhexyl) phthalate. J Enzyme Inhib Med Chem. 2016;31(3):448-55. doi: 10.3109/14756366.2015.1037748..

29. Krumova P, Reyniers L, Meyer M, Lobbestael E, Stauffer D, Gerrits B, Muller L, Hoving S, Kaupmann K, Voshol J, Fabbro D, Bauer A, Rovelli G, Taymans JM, Bouwmeester T, Baekelandt V. Chemical genetic approach identifies microtubule affinity-regulating kinase 1 as a leucine-rich repeat kinase 2 substrate. FASEB J. 2015 Jul;29(7):2980-92. doi: 10.1096/fj.14-262329.

30. Rascol O, Perez-Lloret S, Damier P, Delval A, Derkinderen P, Destée A, Meissner WG, Tison F, Negre-Pages L. Falls in ambulatory non-demented patients with Parkinson’s disease. J Neural Transm (Vienna). 2015 Oct;122(10):1447-55. doi: 10.1007/s00702-015-1396-2.

31. Moreau C, Meguig S, Corvol JC, Labreuche J, Vasseur F, Duhamel A, Delval A, Bardyn T, Devedjian JC, Rouaix N, Petyt G, Brefel-Courbon C, Ory-Magne F, Guehl D, Eusebio A, Fraix V, Saulnier PJ, Lagha-Boukbiza O, Durif F, Faighel M, Giordana C, Drapier S, Maltête D, Tranchant C, Houeto JL, Debû B, Azulay JP, Tison F, Destée A, Vidailhet M, Rascol O, Dujardin K, Defebvre L, Bordet R, Sablonnière B, Devos D; Parkgait-II Study Group. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson’s disease. Brain. 2015 May;138(Pt 5):1271-83. doi: 10.1093/brain/awv063.

32. Poewe W, Seppi K, Fitzer-Attas CJ, Wenning GK, Gilman S, Low PA, Giladi N, Barone P, Sampaio C, Eyal E, Rascol O; Rasagiline-for-MSA investigators. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. Lancet Neurol. 2015 Feb;14(2):145-52. doi: 10.1016/S1474-4422(14)70288-1.

33. Méquinion M, Caron E, Zgheib S, Stievenard A, Zizzari P, Tolle V, Cortet B, Lucas S, Prévot V, Chauveau C, Viltart O. Physical activity: benefit or weakness in metabolic adaptations in a mouse model of chronic food restriction? Am J Physiol Endocrinol Metab. 2015 Feb 1;308(3):E241-55. doi: 10.1152/ajpendo.00340.2014.

 

PUBLICATIONS 2014

34. Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism. Taymans JM, Baekelandt V. Front Genet. 2014 Nov 7;5:382. doi: 10.3389/fgene.2014.00382. Review.

35. Bourdon F, Lecoeur M, Lebègue N, Gressier B, Luyckx M, Odou P, Dine T, Goossens JF, Kambia N. Pharmacokinetic evaluation of a novel benzopyridooxathiazepine derivative as a potential anticancer agent. Pharmacology. 2014;94(3-4):170-8. doi: 10.1159/000368084.

36. Göring S, Taymans JM, Baekelandt V, Schmidt B. Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond. Bioorg Med Chem Lett. 2014 Oct 1;24(19):4630-4637. doi: 10.1016/j.bmcl.2014.08.049.

37. Taymans JM, Baekelandt V, Harvey K. Regulation and targeting of enzymes mediating Parkinson’s disease pathogenesis: focus on Parkinson’s disease kinases, GTPases, and ATPases. Front Mol Neurosci. 2014 Jul 29;7:71. doi: 10.3389/fnmol.2014.00071.

38. Delplanque J, Devos D, Huin V, Genet A, Sand O, Moreau C, Goizet C, Charles P, Anheim M, Monin ML, Buée L, Destée A, Grolez G, Delmaire C, Dujardin K, Dellacherie D, Brice A, Stevanin G, Strubi-Vuillaume I, Dürr A, Sablonnière B. MEM240 mutations cause spinocerebellar ataxia 21 with mental retardation and severe cognitive impairment. Brain. 2014 Oct;137(Pt 10):2657-63. doi: 10.1093/brain/awu202.

39. Reyniers L, Del Giudice MG, Civiero L, Belluzzi E, Lobbestael E, Beilina A, Arrigoni G, Derua R, Waelkens E, Li Y, Crosio C, Iaccarino C, Cookson MR, Baekelandt V, Greggio E, Taymans JM. Differential protein-protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathways. J Neurochem. 2014 Oct;131(2):239-50. doi: 10.1111/jnc.12798.

40. Vancraenenbroeck R, De Raeymaecker J, Lobbestael E, Gao F, De Maeyer M, Voet A, Baekelandt V, Taymans JM. In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2. Front Mol Neurosci. 2014 Jun 3;7:51. doi: 10.3389/fnmol.2014.00051.

41. Taymans JM. Can the increasing number of newly developed leucine-rich repeat kinase 2 inhibitors validate or invalidate a potential disease-modifying therapeutic approach for Parkinson’s disease? Expert Opin Ther Pat. 2014 Jul;24(7):727-30. doi: 10.1517/13543776.2014.915945.

42. Perez-Lloret S, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Meissner WG, Schelosky L, Tison F, Rascol O.Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease. JAMA Neurol. 2014 Jul 1;71(7):884-90. doi: 10.1001/jamaneurol.2014.753.

43. Annic A, Moreau C, Salleron J, Devos D, Delval A, Dujardin K, Touzet G, Blond S, Destée A, Defebvre L. Predictive factors for improvement of gait by low-frequency stimulation in Parkinson’s disease. J Parkinsons Dis. 2014;4(3):413-20. doi: 10.3233/JPD-130337.

44. Chung SJ, Biernacka JM, Armasu SM, Anderson K, Frigerio R, Aasly JO, Annesi G, Bentivoglio AR, Brighina L, Chartier-Harlin MC, Goldwurm S, Hadjigeorgiou G, Jasinska-Myga B, Jeon BS, Kim YJ, Krüger R, Lesage S, Markopoulou K, Mellick G, Morrison KE, Puschmann A, Tan EK, Crosiers D, Theuns J, Van Broeckhoven C, Wirdefeldt K, Wszolek ZK, Elbaz A, Maraganore DM; Genetic Epidemiology of Parkinson’s Disease Consortium. Alpha-synuclein repeat variants and survival in Parkinson’s disease. Mov Disord. 2014 Jul;29(8):1053-7. doi: 10.1002/mds.25841. Epub 2014 Feb 27.

45. Beilina A, Rudenko IN, Kaganovich A, Civiero L, Chau H, Kalia SK, Kalia LV, Lobbestael E, Chia R, Ndukwe K, Ding J, Nalls MA; International Parkinson’s Disease Genomics Consortium; North American Brain Expression Consortium, Olszewski M, Hauser DN, Kumaran R, Lozano AM, Baekelandt V, Greene LE, Taymans JM, Greggio E, Cookson MR. Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2626-31. doi: 10.1073/pnas.1318306111.

46. Désaméricq G, Dolbeau G, Verny C, Charles P, Durr A, Youssov K, Simonin C, Azulay JP, Tranchant C, Goizet C, Damier P, Broussolle E, Demonet JF, Morgado G, Cleret de Langavant L, Macquin-Mavier I, Bachoud-Lévi AC, Maison P. Effectiveness of anti-psychotics and related drugs in the Huntington French-speaking group cohort. PLoS One. 2014 Jan ;9(1):e85430.doi:10.1371/journal.pone.0085430.

47. Lenglet T, Lacomblez L, Abitbol JL, Ludolph A, Mora JS, Robberecht W, Shaw PJ, Pruss RM, Cuvier V, Meininger V; Mitotarget study group. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur J Neurol. 2014 Mar;21(3):529-36. doi: 10.1111/ene.12344.

48. Schreurs S, Gerard M, Derua R, Waelkens E, Taymans JM, Baekelandt V, Engelborghs Y. In vitro phosphorylation does not influence the aggregation kinetics of WT α-synuclein in contrast to its phosphorylation mutants. Int J Mol Sci. 2014 Jan 15;15(1):1040-67. doi: 10.3390/ijms15011040.

49. Tard C, Dujardin K, Bourriez JL, Destée A, Derambure P, Defebvre L, Delval A. Attention modulates step initiation postural adjustments in Parkinson freezers. Parkinsonism Relat Disord. 2014 Mar;20(3):284-9. doi: 10.1016/j.parkreldis.2013.11.016.

50. Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, Destée A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O; NS-Park CIC Network.Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology. 2014 Jan 28;82(4):300-7. doi: 10.1212/WNL.0000000000000050.

51. Law BM, Spain VA, Leinster VH, Chia R, Beilina A, Cho HJ, Taymans JM, Urban MK, Sancho RM, Blanca Ramírez M, Biskup S, Baekelandt V, Cai H, Cookson MR, Berwick DC, Harvey K.A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylation. J Biol Chem. 2014 Jan 10;289(2):895-908. doi: 10.1074/jbc.M113.507913. Epub 2013 Nov 25.

52. Mutez E, Nkiliza A, Belarbi K, de Broucker A, Vanbesien-Mailliot C, Bleuse S, Duflot A, Comptdaer T, Semaille P, Blervaque R, Hot D, Leprêtre F, Figeac M, Destée A, Chartier-Harlin MC. Involvement of the immune system, endocytosis and EIF2 signaling in both genetically determined and sporadic forms of Parkinson’s disease. Neurobiol Dis. 2014 Mar;63:165-70. doi: 10.1016/j.nbd.2013.11.007.

53. Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, Jonneaux A, Ryckewaert G, Garçon G, Rouaix N, Duhamel A, Jissendi P, Dujardin K, Auger F, Ravasi L, Hopes L, Grolez G, Firdaus W, Sablonnière B, Strubi-Vuillaume I, Zahr N, Destée A, Corvol JC, Pöltl D, Leist M, Rose C, Defebvre L, Marchetti P, Cabantchik ZI, Bordet R. Targeting chelatable iron as a therapeutic modality in Parkinson’s disease. Antioxid Redox Signal. 2014 Jul 10;21(2):195-210. doi: 10.1089/ars.2013.5593.

54.Devos D, Moreau C, Maltête D, Lefaucheur R, Kreisler A, Eusebio A, Defer G, Ouk T, Azulay JP, Krystkowiak P, Witjas T, Delliaux M, Destée A, Duhamel A, Bordet R, Defebvre L, Dujardin K. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson’s disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry. 2014 Jun;85(6):668-74. doi: 10.1136/jnnp-2013-306439.

 

PUBLICATIONS 2013

55. Garraux G, Phillips C, Schrouff J, Kreisler A, Lemaire C, Degueldre C, Delcour C, Hustinx R, Luxen A, Destée A, Salmon E. Multiclass classification of FDG PET scans for the distinction between Parkinson’s disease and atypical parkinsonian syndromes. Neuroimage Clin. 2013 Jun 14;2:883-93. doi: 10.1016/j.nicl.2013.06.004.

56. Belarbi K, Rosi S.Modulation of adult-born neurons in the inflamed hippocampus. Front Cell Neurosci. 2013 Sep 6;7:145. doi: 10.3389/fncel.2013.00145. Review.

57. Heckman MG, Elbaz A, Soto-Ortolaza AI, Serie DJ, Aasly JO, Annesi G, Auburger G, Bacon JA, Boczarska-Jedynak M, Bozi M, Brighina L, Chartier-Harlin MC, Dardiotis E, Destée A, Ferrarese C, Ferraris A, Fiske B, Gispert S, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Jasinska-Myga B, Jeon BS, Kim YJ, Klein C, Kruger R, Kyratzi E, Lin CH, Lohmann K, Loriot MA, Lynch T, Mellick GD, Mutez E, Opala G, Park SS, Petrucci S, Quattrone A, Sharma M, Silburn PA, Sohn YH, Stefanis L, Tadic V, Tomiyama H, Uitti RJ, Valente EM, Vassilatis DK, Vilariño-Güell C, White LR, Wirdefeldt K, Wszolek ZK, Wu RM, Xiromerisiou G, Maraganore DM, Farrer MJ, Ross OA; Genetic Epidemiology Of Parkinson’s Disease (GEO-PD) Consortium. Protective effect of LRRK2 p.R1398H on risk of Parkinson’s disease is independent of MAPT and SNCA variants. Neurobiol Aging. 2014 Jan;35(1):266.e5-14. doi: 10.1016/j.neurobiolaging.2013.07.013.

58. Heckman MG, Soto-Ortolaza AI, Aasly JO, Abahuni N, Annesi G, Bacon JA, Bardien S, Bozi M, Brice A, Brighina L, Carr J, Chartier-Harlin MC, Dardiotis E, Dickson DW, Diehl NN, Elbaz A, Ferrarese C, Fiske B, Gibson JM, Gibson R, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Boczarska-Jedynak M, Jasinska-Myga B, Jeon BS, Kim YJ, Klein C, Kruger R, Kyratzi E, Lesage S, Lin CH, Lynch T, Maraganore DM, Mellick GD, Mutez E, Nilsson C, Opala G, Park SS, Petrucci S, Puschmann A, Quattrone A, Sharma M, Silburn PA, Sohn YH, Stefanis L, Tadic V, Theuns J, Tomiyama H, Uitti RJ, Valente EM, Van Broeckhoven C, van de Loo S, Vassilatis DK, Vilariño-Güell C, White LR, Wirdefeldt K, Wszolek ZK, Wu RM, Hentati F, Farrer MJ, Ross OA; Genetic Epidemiology of Parkinson’s Disease (GEO-PD) Consortium. Population-specific frequencies for LRRK2 susceptibility variants in the Genetic Epidemiology of Parkinson’s Disease (GEO-PD) Consortium. Mov Disord. 2013 Oct;28(12):1740-4. doi: 10.1002/mds.25600.

59. Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord. 2013 Nov;28(13):1838-46. doi: 10.1002/mds.25561.

60. Simonin C, Duru C, Salleron J, Hincker P, Charles P, Delval A, Youssov K, Burnouf S, Azulay JP, Verny C, Scherer C, Tranchant C, Goizet C, Debruxelles S, Defebvre L, Sablonnière B, Romon-Rousseaux M, Buée L, Destée A, Godefroy O, Dürr A, Landwehrmeyer B; REGISTRY Study of the European Huntington’s Disease Network, Bachoud-Levi AC, Richard F, Blum D, Krystkowiak P; Huntington French Speaking Network. Association between caffeine intake and age at onset in Huntington’s disease. Neurobiol Dis. 2013 Oct;58:179-82. doi: 10.1016/j.nbd.2013.05.013.

67. Belarbi K, Jopson T, Arellano C, Fike JR, Rosi S. CCR2 deficiency prevents neuronal dysfunction and cognitive impairments induced by cranial irradiation. Cancer Res. 2013 Feb 1;73(3):1201-10. doi: 10.1158/0008-5472.CAN-12-2989.

69. Burnouf S, Martire A, Derisbourg M, Laurent C, Belarbi K, Leboucher A, Fernandez-Gomez FJ, Troquier L, Eddarkaoui S, Grosjean ME, Demeyer D, Muhr-Tailleux A, Buisson A, Sergeant N, Hamdane M, Humez S, Popoli P, Buée L, Blum D. NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a Tau transgenic model. Aging Cell. 2013 Feb;12(1):11-23. doi: 10.1111/acel.12018.

69. Moreau C, Delval A, Tiffreau V, Defebvre L, Dujardin K, Duhamel A, Petyt G, Hossein-Foucher C, Blum D, Sablonnière B, Schraen S, Allorge D, Destée A, Bordet R, Devos D.Memantine for axial signs in Parkinson’s disease: a randomised, double-blind, placebo-controlled pilot study. J Neurol Neurosurg Psychiatry. 2013 May;84(5):552-5. doi: 10.1136/jnnp-2012-303182.

70. Ando K, Dourlen P, Sambo AV, Bretteville A, Bélarbi K, Vingtdeux V, Eddarkaoui S, Drobecq H, Ghestem A, Bégard S, Demey-Thomas E, Melnyk P, Smet C, Lippens G, Maurage CA, Caillet-Boudin ML, Verdier Y, Vinh J, Landrieu I, Galas MC, Blum D, Hamdane M, Sergeant N, Buée L. Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker. Neurobiol Aging. 2013 Mar;34(3):757-69. doi: 10.1016/j.neurobiolaging.2012.08.004.